Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Business & Industry
- FDA grants Breakthrough Therapy Designation for Roche's Hemlibra in haemophilia A without inhibitors
- Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
- Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford
- Bristol-Myers Squibb announces worldwide collaboration with Janssen to develop and commercialize next-generation cardiovascular therapy
- GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics
Research & Development
- Personalized tumor vaccine shows promise in pilot trial
- New class of drugs could help tackle treatment-resistant cancers
- New immunotherapy for lung cancer shows promise of success
- Human drug trials are compromised by poor reporting of animal research
- 'Coffee filter' helps make new cancer drug Z-endoxifen 1,000 times cheaper
- Researchers propose key elements of antimicrobial stewardship for hospitals worldwide
- When drugs are wrong, skipped or make you sick: The cost of non-optimized medications
Conferences & Events
- SMi presents the 2nd annual conference on Pharmaceutical Microbiology West Coast
- Introducing SMi's 6th annual conference on Pharmaceutical Freeze Drying Technology this June 2018
- Adaptive Designs in Clinical Trials Conference 2018
- Drug Safety 2018
- Controlled Release Delivery Conference 2018
- Superbugs & Superdrugs Conference 2018
- Highly Potent Active Pharmaceutical Ingredients (HPAPI) Conference 2018
Regulatory Affairs
- FDA permits marketing of artificial intelligence-based device to detect certain diabetes-related eye problems
- FDA approves new treatment for certain digestive tract cancers
- FDA approves first treatment for breast cancer with a certain inherited genetic mutation
- FDA updates the label of Tasigna to reflect that certain patients with a type of leukemia may be eligible to stop treatment after sustained response
- FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss
- FDA launches new tool for sharing information that allows doctors to better manage antibiotic use; improve patient care
- FDA launches public education campaign to encourage adult smokers trying to quit cigarettes